<DOC>
	<DOCNO>NCT00497497</DOCNO>
	<brief_summary>This Phase Ib , open-label , multicenter , dose-escalation study design ass PRO95780 combination two different irinotecan-containing regimen safe tolerable patient metastatic colorectal cancer ( mCRC ) progress follow , tolerate , first-line therapy 5-fluorouracil- , oxaliplatin- , bevacizumab-containing regimen . This study also make preliminary assessment anti-tumor activity PRO95780 combination irinotecan cetuximab FOLFIRI regimen plus bevacizumab .</brief_summary>
	<brief_title>A Study PRO95780 Combination With Cetuximab Irinotecan Chemotherapy FOLFIRI Regimen With Bevacizumab Patients With Previously Treated Metastatic Colorectal Cancer ( APM4187g )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed informed consent Age â‰¥ 18 year Histologically confirm CRC evidence metastasis measurable tumor lesion Documented disease progression follow , intolerance , treatment 5fluorouracil , oxaliplatin , bevacizumabbased therapy Life expectancy &gt; 3 month For patient reproductive potential ( male female ) , use reliable mean contraception ( e.g. , contraceptive pill , intrauterine device [ IUD ] , physical barrier ) throughout trial 6 month follow final exposure study treatment Willingness capability accessible study followup Patients Kras mutation exclude receive cetuximabcontaining regimen Prior radiotherapy measurable metastatic lesion ( ) use response assessment , unless lesion progress subsequent radiotherapy Recent radiotherapy peripheral lesion , thoracic , abdominal , pelvic field Recent chemotherapy , hormonal therapy , immunotherapy Evidence clinically detectable ascites Other invasive malignancy within 5 year History evidence active central nervous system ( CNS ) disease Current recent participation another experimental drug study Clinically significant cardiovascular disease Active infection require parenteral antibiotic Recent major surgical procedure , open biopsy , significant traumatic injury , fine needle aspiration , anticipation need major surgical procedure course study Known suspect positive human immunodeficiency virus ( HIV ) Known positive hepatitis C hepatitis B surface antigen History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug specify study treatment Pregnancy ( positive pregnancy test ) breast feed Serious , nonhealing wound , ulcer , bone fracture Known sensitivity product administer study Any disorder compromise ability patient provide write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>CRC</keyword>
	<keyword>Colon cancer</keyword>
	<keyword>Avastin</keyword>
	<keyword>APM4187g</keyword>
</DOC>